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Esters of p-hydroxybenzoic acid (parabens) areadded to a commercially available  LISS(C-LISS)to retard microbial growth. We have described examples of anti-Jka that react only when parabens
or related compounds are present in the reaction mixture.1
Because active compounds had to be present in mixtures
of serum plus RBCs for serologic reactivity to occur, Halima
et al.2 suggested that these examples of anti-Jka react by an
immune complex mechanism. In this report, we describe
the first example of a paraben-dependent antibody to an
Rh protein that does not require the presence of paraben
in the reaction milieu. Rather, this antibody appears to re-
act with a neoantigen formed between propylparaben or re-
lated compounds and an Rh protein.
CASE REPORT
The patient is a 24-year-old untransfused woman who re-
cently moved to the United States from Yemen. She was
seen at the University of Michigan Health Systems (UMHS)
for evaluation of primary infertility; she was treated with
oral clomiphene citrate and Provera, and she subsequently
conceived. This is the patient’s first known pregnancy. We
received blood samples for routine prenatal testing: ABO
and Rh typing and tests for unexpected antibodies.
Her blood typed as group A, R1r (D+C+c+E–e+), and
indirect antiglobulin tests (anti-IgG) for unexpected anti-
bodies by using R1R1 and R2R2 RBCs stored in C-LISS were
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positive. The serum did not react in initial antibody identi-
fication tests performed with RBCs freshly prepared in C-
LISS. However, an apparent anti-D+V/VS was detected by
the IAT using RBCs stored for 2 to 4 hours in C-LISS. More-
over, while the DAT was negative, an autocontrol performed
with the patient’s RBCs that had been stored in C-LISS was
positive (2+).
The outcome of this patient’s pregnancy is unknown.
During this investigation, she was lost to follow-up.
MATERIALS AND METHODS
The LISS solution containing methylparaben and propylpa-
raben is available commercially (Immucor Inc., Norcross,
GA). This reagent is based on the original formulation de-
scribed by Löw and Messeter in 1976,3 and it contains gly-
cine, sodium chloride, and phosphate buffer to give a final
pH of 6.7 and an osmolality of 289 ± 10 mOsm per kg. Me-
thylparaben and propylparaben are added to this solution
by the manufacturer at concentrations of 0.6 g per L and 0.1
g per L, respectively.4 The LISS solution is used for the de-
tection of unexpected antibodies in rou-
tine pretransfusion and perinatal test-
ing. Briefly, RBCs are suspended in the
LISS solution at a concentration of 2 per-
cent. Equal volumes of RBCs and serum
are incubated at 37°C for 10 minutes, af-
ter which the RBCs are washed and
tested with anti-IgG.4
RBCs used in this investigation were
obtained from commercial RBC panels,
volunteer blood donors, or the frozen
rare RBC panels of our institutions. Many
of the latter were obtained through the
Serum, Cells and Rare Fluids Interna-
tional Exchange Program.
LISS additive reagents, PEG, ficin-
treated RBCs, and an acid elution test kit
were from Immucor. Antiglobulin re-
agents and anti-IgG gel cards were from
Ortho Clinical Diagnostics (Raritan, NJ).
In inhibition tests, serial 1-in-2 dilu-
tions of the patient’s serum were mixed
with an equal volume of 0.1-percent pro-
pylparaben in saline. After 30-minute
incubation at room temperature, each
dilution was tested against R2R2 RBCs
that had been incubated in C-LISS. All
other serologic procedures were per-
formed according to the reagent manu-
facturers’ directions or as described else-
where.4 Agglutination reactions were
graded and scored as described by
Marsh.5 Solutions of parabens and re-
lated compounds were made in our in-house prepared LISS
(Löw and Messeter formulation) or in pH 7.3 PBS as de-
scribed previously.1
RESULTS
The initial resolution of the positive screening test for un-
expected antibodies was hampered by the fact that RBCs
stored in C-LISS reacted, but those freshly suspended in C-
LISS did not react. The RBCs used for antibody detection
at UMHS are prepared as 2-mL volumes in C-LISS and used
within 4 hours. In contrast, RBCs used for antibody identi-
fication are suspended in C-LISS and tested immediately.
By use of a panel of RBCs previously incubated with C-LISS
(2 hours at 22-25°C), an antibody with D+V/VS specificity
was identified. However, while an autocontrol (patient’s
RBCs incubated in C-LISS) reacted, the DAT did not.
Table 1 summarizes the results of tests with RBCs of
common and uncommon Rh phenotypes incubated in C-
LISS. Our patient’s antibody reacted with most partial D
RBCs to the same degree as it did with RBCs carrying a nor-
TABLE 1. Reactions of paraben-dependent antibody with various Rh
phenotypes
Score*
Rh phenotype n† 10 9 8 6 5 4 3 0
Reactive RBCs RzR1 1 1
R1R1 12 5 4 3
R2R2 11 5 3 3
R1r‡ 2 2
R1R2 1 1
Ro 2 1 1
rrV+ 7 3 2 2
RoV+VS+ 2 2
R1r LW(a–b–) 1 1
DIIIa§ 1 1
DIIIc 2 1 1
DIVa 2 1 1
DIVb 2 1 1
DVa 2 2
DVI Type 1 2 2
DVI Type 2 2 1 1
DVI Type 3 1 1
DVII 2 1 1






Har 2 1 1
r´´G 1 1
rGr 1 1





* Graded agglutination reaction based on the scoring system of Marsh.5
† Number of each phenotype tested.
‡ One R1r sample was the patient’s RBCs (autocontrol).
§ To the best of our knowledge, all partial D phenotypes tested were associated with a
ce (r) haplotype.
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mal D, and it reacted with D– RBCs that are either G+,
V+VS+, or V–VS+. Surprisingly, while r´r and r´´r RBCs did
not react, ryr RBCs reacted.
The active ingredient in C-LISS proved to be propylpa-
raben. The other ingredients of C-LISS were not required,
as antibody reactivity was not demonstrable by use of an in-
house preparation of Löw and Messeter’s LISS3 to which no
parabens were added, and it could be demonstrated with
RBCs incubated in 0.1-percent propylparaben in normal
saline. Reactivity with C-LISS-stored RBCs could not be in-
hibited by 0.1-percent (wt/vol) propylparaben. The activ-
ity against D+V– and D–V+VS+ RBCs coated with propylpa-
raben was not separable by adsorption-elution. The anti-Rh
activity was demonstrable in gel and ficin-antiglobulin
tests, but only with RBCs previously incubated in C-LISS.
Furthermore, and in contrast to the previously described
examples of paraben anti-Jka, propylparaben did not have
to be present in the reaction milieu for antibody detection;
RBCs incubated in C-LISS and then washed and tested by
gel reacted.
Methylparaben is also added to C-LISS. However, D+
RBCs incubated in methylparaben in either LISS or saline
and then tested did not react. D+ RBCs incubated in a num-
ber of commercially available LISS additive solutions or
PEG also did not react.
Figure 1 shows the structure of propylparaben and re-
lated compounds that were studied. Those compounds
shown across the top of the figure were all capable of mani-
festing the paraben-dependent anti-Rh. Along the bottom
are the structures of the p, m, and o forms of methyl
hydroxybenzoate. Methyl-p-hydroxybenzoate (methylpa-
raben) and methyl-m-hydroxybenzoate were inactive com-
pounds, whereas methyl-o-hydroxybenzoate (methyl sali-
cylate, Wintergreen) reacted.
DISCUSSION
Ohsako and Matsumoto6 showed that derivatives of
hydroxybenzoates are transported across the RBC mem-
brane and suggested that Band 3 (anion exchanger, AE1), a
multipass membrane glycoprotein,7 is the transport pro-
tein. It is of interest that, on the basis of the presumed to-
pology, Rh is also predicted to be a multipass transport pro-
tein that associates with Band 3 in the RBC membrane.8,9 It
is of further interest, in light of previous reports of paraben-
dependent anti-Jka,1,2 that the urea transporter protein,
which serves as the carrier molecule for the Kidd blood
group antigens, is a multipass protein.10 It is tempting to
speculate, therefore, that propylparaben and related reac-
tive compounds bind to an Rh protein or to an epitope de-
rived from the interaction of Rh with another RBC mem-
brane protein, to form a neoantigen that is recognized by
the antibody present in our patient’s serum. This neoanti-
gen hypothesis is somewhat analogous to the mechanism
proposed for some cephalosporin-induced autoantibod-
ies.11
An initial review of the chemical structure of the active
parabens (Fig. 1) suggested that ethylene (CH2-CH3) groups
contribute to this binding. However, CH2-CH3  groups are
not present in the alkyl chains of methyl salicylate and 2-
phenoxyethanol, which also are active
compounds.
It is plausible that the binding of
phenol derivatives to RBC membranes is
not directly related to a specific chemi-
cal group. In fact, our data suggest that
the binding of phenol derivatives is re-
lated to their weak hydrophobicity (e.g.,
increased lipophilic characteristics),
which would result in a stronger associa-
tion with both the bilayer lipid mem-
branes of RBCs and the multipass Rh
protein that resides within the lipid
membranes.
It is known that alkyl groups of phe-
nol derivatives can shield the hydroxyl
group and that this makes the derivative
less hydrophilic, or more lipophilic (i.e.,
increases their binding to lipids).12 With
methylparaben, which has a relatively
short alkyl group, there is little shielding.
As the length of the alkyl substitution on
the carboxyl group of paraben increases
beyond the methyl group (see Fig. 1),
Fig. 1. Structures of parabens and related compounds used. All those on the top row
reacted; on the bottom row, methylparaben and methyl-m-hydroxybenzoate did not
react, and methyl salicylate reacted.
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there can be better interaction with the p-hydroxyl group.
In the case of methyl salicylate, in which the methyl and
hydroxyl groups are in close proximity to each other, this
shielding readily occurs. This hypothesis is supported by
the fact that methyl salicylate (o-alkyl group) is one-fourth
as soluble in water as is methylparaben (p-alkyl group).13 It
is interesting that clomiphene citrate, which our patient
was receiving, has a purported metabolite containing a
phenyl group with adjacent methoxy and hydroxyl groups
in the same configuration as those of methyl salicylate.14,15
Unfortunately, the data on Rh variant RBCs shed little
light on the precise role of the Rh proteins RhD and RhCE
in the binding of the paraben-dependent antibody. These
tests were performed to determine if there is a specific por-
tion of Rh protein that must be present for binding to oc-
cur. Initially, tests with RBCs of common Rh phenotypes
suggested a specificity of anti-D plus anti-V and/or anti-VS,
as D+, D–V+ and D–VS+ RBCs reacted, but RBCs of other
common D– phenotypes did not. Further testing with RBCs
of uncommon Rh phenotypes showed that the antibody
reacted with cells expressing hybrid Rh proteins with only
small portions derived from RHD. Such RBCs (e.g., rG, r´´G,
and r´s) are not considered to be D+. With partial D pheno-
type RBCs, the reaction strength was variable among RBCs
from the same category, and it did not appear to be related
to the number of D epitopes expressed (e.g., Ro
Har and some
DVI RBCs gave the same reactions as normal D+ and DIII
RBCs).
Molecular studies have shown that many Rh pheno-
types are the result of gene rearrangements encoding hy-
brid RhD/RhCE proteins.9 Comparison of the probable
molecular basis of the RBC phenotypes that react with our
patient’s serum does not reveal a common determinant.
While most reactive RBCs express a portion of RhD encoded
by exon 2 of RHD, that is the only portion expressed on rG
RBCs. In contrast, RoHar RBCs, which also react, express only
a portion of RhD derived from exon 5 of RHD.
The most intriguing finding of all is the reactivity of ryr
(CE/ce) RBCs in the face of negative tests with r´r (Ce/ce)
and r´´r (cE/ce) RBCs. It is assumed that the ry haplotype
involves normal RHCE-encoding sequences specific for C
and E antigen expression. However, the reactivity of ry RBCs
may indicate that ry can be encoded by a hybrid gene com-
posed of portions of RHD and RHCE.
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